IMMUNOLOGY

TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state

Yrina Rochman,[1,2]* Krista Dienger-Stambaugh,[1] Phoebe K. Richgels,[1] Ian P. Lewkowich,[1] Andrey V. Kartashov,[3] Artem Barski,[3,4] Gurjit K. Khurana Hershey,[5] Warren J. Leonard,[2] Harinder Singh[1]*

Pathogenic T helper 2 (T$_H$2) cells, which produce increased amounts of the cytokines interleukin-5 (IL-5) and IL-13, promote allergic disorders, including asthma. Thymic stromal lymphopoietin (TSLP), a cytokine secreted by epithelial and innate immune cells, stimulates such pathogenic T$_H$2 cell responses. We found that TSLP signaling in mouse CD4+ T cells initiated transcriptional changes associated with T$_H$2 cell programming. IL-4 signaling amplified and stabilized the genomic response of T cells to TSLP, which increased the frequency of T cells producing IL-4, IL-5, and IL-13. Furthermore, the TSLP- and IL-4–programmed T$_H$2 cells had a pathogenic phenotype, producing greater amounts of IL-5 and IL-13 and other proinflammatory cytokines than did T$_H$2 cells stimulated with IL-4 alone. TSLP-mediated T$_H$2 cell induction involved distinct molecular pathways, including activation of the transcription factor STAT5 through the kinase JAK2 and repression of the transcription factor BCL6. Mice that received wild-type CD4+ T cells had exacerbated pathogenic T$_H$2 cell responses upon exposure to house dust mites compared to mice that received TSLP receptor–deficient CD4+ T cells. Transient TSLP signaling stably programmed pathogenic potential in memory T$_H$2 cells. In human CD4+ T cells, TSLP and IL-4 promoted the generation of T$_H$2 cells that produced greater amounts of IL-5 and IL-13. Compared to healthy controls, asthmatic children showed enhancement of such T cell responses in peripheral blood. Our data support a sequential cytokine model for pathogenic T$_H$2 cell differentiation and provide a mechanistic basis for the therapeutic targeting of TSLP signaling in human allergic diseases.

INTRODUCTION

T helper 2 (T$_H$2) cells are effector T cells that differentiate from naïve CD4+ T cells to produce the cytokines interleukin-4 (IL-4), IL-5, and IL-13. They enable protection against extracellular parasites but also promote allergic inflammation (1). IL-4 is not only produced by T$_H$2 cells but also required for their differentiation in vitro and in vivo (2). IL-4 signaling results in the activation of the transcription factor signal transducer and activator of transcription 6 (STAT6), which, in turn, induces the expression of GATA3, which encodes a key T$_H$2 cell–specific transcription factor. STAT6 and GATA3 (GATA binding protein 3) bind to regulatory regions of the T$_H$2 cytokine locus and activate expression of the IL4, IL5, and IL13 genes. Although IL-4 is produced by activated CD4+ T cells that are differentiating into T$_H$2 cells, the source of IL-4 in vivo during the initial stages of T cell activation remains unresolved. Several studies have identified additional cytokines that promote T$_H$2 cell responses in vivo (1, 3–5). One of these is thymic stromal lymphopoietin (TSLP), which is produced by epithelial cells upon injury, dysfunction, or infection. Furthermore, TSLP is also produced by dendritic cells (DCs) and, thereby, could function during T cell priming in lymph nodes (6, 7).

TSLP is strongly implicated in the pathogenesis of T$_H$2 cell–mediated allergic disorders, including atopic dermatitis, allergic asthma, food allergy, and eosinophilic esophagitis (8). Some studies have reported that TSLP primarily acts on DCs to promote pathogenic T$_H$2 responses (9, 10). However, others have implicated a role for TSLP signaling in CD4+ T cells in T$_H$2 cell–mediated inflammation (11–14). In this regard, ovalbumin (OVA)–sensitized, TSLP receptor (TSLPR)–deficient (Crlf2$^{-/-}$) mice fail to develop an inflammatory T$_H$2 cell response in their lungs to inhaled antigen (15). However, transfer of wild-type (WT) CD4+ T cells that express the TSLPR into OVA-sensitized Crlf2$^{-/-}$ mice promotes allergic inflammation. Similarly, injection of WT CD4+ T cells into Crlf2$^{-/-}$ mice also results in the development of allergic inflammation in the gut to OVA administration (16). Thus, TSLP signaling in CD4+ T cells is required for the generation of robust pathogenic T$_H$2 responses in vivo. However, these analyses have not uncovered a direct role for TSLP in the differentiation of pathogenic T$_H$2 cells.

TSLP signals in mouse and human CD4+ T cells to induce the activation of the transcriptional regulator STAT5 through a pathway requiring the kinases Janus kinase 1 (JAK1) and JAK2 (11, 14). TSLP increases the survival of naïve CD4+ T cells and that of memory T$_H$2 cells; the latter are a form of quiescent T$_H$2 cells that can be rapidly reactivated upon exposure to cognate antigens (17). TSLP induces the secretion of IL-4 and IL-9 in conjunction with T cell receptor (TCR) activation (12, 13, 18). In turn, IL-4 increases the expression of the TSLPR on CD4+ T cells, suggesting a positive feedback loop between the two cytokines (19). We explored whether TSLP could directly promote the differentiation of naïve CD4+ T cells into T$_H$2 cells, particularly a "pathogenic" effector state that produces large amounts of IL-5 and IL-13. Furthermore, we analyzed the interplay between TSLP signaling and IL-4 signaling in the initiation and amplification of the T$_H$2 cell differentiation response and its culmination into a pathogenic state. Finally, we assessed the response of human CD4+ T cells to TSLP signaling and whether such potentially pathogenic T$_H$2 cell responses were enhanced in the context of asthma.

[1]Division of Immunobiology and the Center for Systems Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. [2]Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA. [3]Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. [4]Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. [5]Division of Asthma Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
*Corresponding author. Email: yrina.rochman@cchmc.org (Y.R.); harinder.singh@cchmc.org (H.S.)

RESULTS

TSLP directly promotes T_H2 cell differentiation

To test the role of TSLP signaling in promoting T_H2 cell differentiation, we activated naïve $CD4^+$ T cells in vitro with antibodies stimulating CD3 and CD28 and neutralizing interferon-γ (IFN-γ) in the presence of IL-4, TSLP, or both for 3 days. Compared with IL-4–induced T_H2 cell differentiation, TSLP statistically significantly increased the frequency of T_H2 cells producing IL-4, IL-5, and IL-13 (Fig. 1, A and B) and increased the amount of IL-5 and IL-13 produced per cell (fig. S1A). Increase in both the frequency and amplitude of production

Fig. 1. TSLP signaling increases the frequency of T_H2 cells expressing IL-4, IL-5, and IL-13. (**A** and **B**) To generate T helper 2 (T_H2) cells, naïve $CD4^+$ T cells were activated for 3 days with antibodies against CD3 (αCD3; 5 μg/ml) and CD28 (αCD28; 2 μg/ml) with neutralization of interferon-γ (αIFN-γ; 10 μg/ml) in the absence (T_H0) or presence of the indicated cytokines at the following concentrations: interleukin-4 (IL-4) (20 ng/ml; T_H2^{IL-4}), thymic stromal lymphopoietin (TSLP) (40 ng/ml; T_H2^{TSLP}), IL-4 and TSLP ($T_H2^{IL-4+TSLP}$), or IL-7 (20 ng/ml). (A) The frequency of cytokine-positive cells in a representative experiment is shown. Top: Cells were assessed for IL-13 and IL-4 by flow cytometry. Bottom: Cells were assessed for IL-13 and IL-5. Data in (B) are pooled from 10 independent experiments. ns, not significant. (**C** and **D**) Naïve $CD4^+$ T cells were stimulated with indicated cytokines at the same concentrations as those in (A) for 15 min, and then, the phosphorylation of signal transducer and activator of transcription 5 (STAT5) was analyzed by flow cytometry with an antibody against phosphorylated STAT5 (pSTAT5). (C) Geometric mean fluorescent intensity (GMFI; x axes) of pSTAT5 in a representative experiment. Data in (D) are pooled from seven independent experiments. Quantitative data are means ± SEM and were analyzed by one-way analysis of variance (ANOVA). *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$, and ****$P \leq 0.0001$.

resulted in increased secretion of IL-4, IL-5, and IL-13 (fig. S1, B and C). Notably, the addition of exogenous IL-4 during TSLP stimulation did not augment T_H2 cytokine production (Fig. 1, A and B). Hereafter, we refer to TSLP-derived T_H2 cells as T_H2^{TSLP} cells and T_H2 cells produced by exogenously added IL-4 as T_H2^{IL-4} cells. TSLP did not affect the survival or proliferation of activated $CD4^+$ T cells (fig. S1, D and E) nor the induction of interferon regulatory factor 4 (IRF4) (fig. S1F), which is an essential transcription factor for T cell activation and T_H2 cell differentiation (20, 21). Consistent with a previous report (14), TSLP reduced the apoptosis of naïve $CD4^+$ T cells (fig. S1D). These results suggest that TSLP signaling increases the frequency of T_H2 cells that produce IL-4, IL-5, and IL-13 through mechanisms that do not involve altered IRF4 activation or enhanced survival or proliferation of activated cells.

TSLP signaling is mediated by a receptor complex containing IL-7 receptor α (IL-7Rα) and TSLPR (22). Given the shared IL-7Rα subunit between TSLPR and IL-7R, we tested the effect of IL-7 on T_H2 cell differentiation in relation to TSLP. Although IL-7 also stimulated the production of IL-13–positive cells that were indicative of T_H2 cell differentiation, IL-7 was less effective than TSLP (Fig. 1, A and B) despite inducing greater STAT5 activation under the culture conditions (Fig. 1, C and D). These results suggest that TSLP may use one or more additional signaling pathways in conjunction with the JAK-STAT5 pathway to efficiently drive T_H2 cell differentiation.

TSLP initiates T_H2 cell programming in the absence of IL-4

Although TSLP signaling induced an increase in the abundance of IL-4 (fig. S1B) and IL-4Rα (fig. S2A), which promote T_H2 cell differentiation (12), the observation that TSLP increased the frequency of IL-5– and IL-13–positive cells to a greater extent than did IL-4 alone suggested that TSLP could function independently of or in synergy with IL-4. To test the action of TSLP in the absence of IL-4 signaling, we included function-blocking antibodies to IL-4 and IL-4Rα during $CD4^+$ T cell differentiation. Even in the presence of the function-blocking antibodies, TSLP stimulated the induction of *Il4*, *Il5*, and *Il13* expression within 24 hours of $CD4^+$ T cell activation (Fig. 2A). However, expression of these T_H2 cytokine genes was not amplified at the later time points in the absence of IL-4. This correlated with the lack of induction of *Gata3* expression by TSLP in the absence of IL-4 signaling, which is consistent with a dependence of *Gata3* expression on the IL-4/STAT6 pathway. As expected, the function-blocking antibodies abolished IL-5 and IL-13 secretion during IL-4–induced T_H2 cell differentiation (Fig. 2B), indicating that this was an effective method for blocking IL-4 signaling. Consistent with the gene expression data (Fig. 2A), TSLP, in the presence of the IL-4– and IL-4Rα (IL-4/IL-4Rα)–blocking antibodies, induced IL-5 and IL-13 secretion but at substantially reduced amounts (Fig. 2B).

To complement the antibody-mediated blockade of IL-4 signaling, we performed similar experiments with $Il4^{-/-}$ $CD4^+$ T cells. As we observed with the IL-4/IL-4Rα–blocking antibodies, activation of $Il4^{-/-}$ $CD4^+$ T cells with TSLP induced production of both IL-5 and IL-13, albeit at reduced amounts than in the presence of exogenously added IL-4 (Fig. 2C). Without exogenously added IL-4, the abundance of GATA3 was not increased (fig. S2B). To examine the potential synergistic actions of TSLP with IL-4 on T_H2 cell differentiation, we activated $Il4^{-/-}$ $CD4^+$ T cells in the presence of TSLP and increasing concentrations of IL-4. At each concentration of IL-4 used, TSLP in conjunction with IL-4 induced a greater increase in the frequency of IL-13–positive cells (Fig. 2, D and E) and the secretion of IL-5 and IL-13 (fig. S2C) than their sum with the individual cytokines

Fig. 2. TSLP initiates T_H2 cell programming, which is amplified by IL-4. (**A** and **B**) Naïve CD4+ T cells were activated with antibodies, as described in Fig.1A, in the presence or absence of blocking antibodies against IL-4 and IL-4Rα (αIL-4/4R). T_H2 cells differentiated in response to IL-4 (T_H2^{IL-4}) served as a control for T_H2 cell induction. (A) Kinetics of induction of the indicated genes as determined by real-time polymerase chain reaction (PCR) analysis. Data are representative of three independent experiments and are means ± SD of replicates from a single experiment. (B) The amounts of the indicated cytokines in the cell culture medium were determined by enzyme-linked immunosorbent assay on day 3. Data are means ± SEM of five experiments and were evaluated by one-way ANOVA. (**C**) Naïve $Il4^{-/-}$ CD4+ T cells were activated as described in Fig.1A in the presence or absence of TSLP (40 ng/ml), IL-4 (20 ng/ml), or both. The amounts of the indicated cytokines in the cell culture medium were analyzed as described in (B). Data are means ± SEM of eight experiments and were analyzed by one-way ANOVA. (**D** and **E**) Naïve $Il4^{-/-}$ CD4+ T cells were activated as described in Fig.1A in the presence or absence of TSLP (40 ng/ml) and the indicated concentrations of IL-4. Cells were assessed for IL-13 and IL-4 content by flow cytometry. Data in (D) are from a representative experiment. Data in (E) are means ± SEM of seven independent experiments and were analyzed by paired, two-tailed t test. *$P \le 0.05$, **$P \le 0.01$, and ****$P \le 0.0001$.

(table S1). Together, these results suggest that TSLP initiates T_H2 cytokine gene expression in the absence of IL-4–mediated GATA3 induction and that TSLP functions with IL-4 to amplify T_H2 cell differentiation (the frequency of cells producing the cytokines) and enhance T_H2 cytokine production (the amount of cytokines produced per cell).

TSLP promotes T_H2 cytokine gene expression by repressing *Bcl6*

We next performed RNA sequencing (RNA-seq) analysis of differentiating T_H2^{IL-4} and T_H2^{TSLP} cells to determine whether they man-

ifested distinctive genomic states. Overall, the genome-wide expression profiles of T_H2^{IL-4} and T_H2^{TSLP} cells were similar to each other and distinguishable from that of T_H0 cells (fig. S3A). T_H2^{IL-4} and T_H2^{TSLP} cells displayed the increased expression of 229 genes and the reduced expression of 148 genes by at least twofold when compared with T_H0 cells (table S2). T_H2^{IL-4} and T_H2^{TSLP} cells showed increased expression of genes required for T_H2 cell differentiation and T cell survival, such as *Il4*, *Gata3*, *Nfil3*, *Batf3*, *Atf3*, *Id2*, *Rbpj*, *Il2ra*, *Bcl2*, and *Il7r* (fig. S3A and table S3). Both IL-4 and TSLP repressed the expression of genes associated with the T_H1 and T_H17 cell lineages, including *Stat4*, *Rorc*, *Zbtb32*, *Bcl6*, *Cd27*, *Cd70*, and *Ccr6*.

To analyze genes that were differentially expressed in T_H2^{TSLP} and T_H2^{IL-4} cells, we focused separately on the induced and repressed genes. Of the 229 induced genes, 134 were differentially expressed by at least twofold in T_H2^{TSLP} versus T_H2^{IL-4} cells at the various time points; 22 of these were increased by TSLP, whereas 112 were increased with IL-4 (Fig. 3A and table S4). Of 22 genes that were preferentially induced in T_H2^{TSLP} cells, most encoded T_H2 cytokines or other proinflammatory mediators. The increased expression of select genes was validated by quantitative polymerase chain reaction (PCR) analysis (Fig. 3B). These results show that T_H2^{TSLP} cells preferentially express a small module of allergy-promoting and proinflammatory cytokine genes and this likely enables their enhanced effector functions.

Of the repressed genes, *Bcl6* was the most differentially affected in T_H2^{TSLP} cells, and this was confirmed by real-time PCR analysis (Fig. 3C), which resulted in reduced protein abundance, as analyzed by flow cytometry (Fig. 3D and fig. S3B). To test whether the repression of *Bcl6* expression by TSLP signaling was required for T_H2 cell differentiation, we transduced activated CD4+ T cells with a retroviral vector encoding *Bcl6*. Enforced expression of BCL6 in activated CD4+ T cells abolished the TSLP-induced expression of T_H2 cytokine genes (Fig. 3E). Our results are consistent with the finding that BCL6 directly represses the *Il13* gene in the context of T follicular helper cell differentiation (23). We therefore propose that the antagonism of *Bcl6* induction by TSLP (Fig. 3D) promotes the increased frequency and cytokine output of IL-13–producing T_H2^{TSLP} cells.

TSLP induces T_H2 cytokine expression through JAK2 and STAT5

To determine whether the JAK-STAT5 pathway activated by TSLP (14), in the absence of IL-4 signaling, was required for the induction of T_H2 cytokine gene expression, we performed experiments with $Il4^{-/-}$ CD4+ T cells and a JAK2-selective inhibitor (14, 24). We confirmed that JAK2 inhibitor II blocked the phosphorylation of STAT5 induced by TSLP (Fig. 4A) but not the phosphorylation of STAT6 induced by IL-4 (fig. S4A) nor the phosphorylation of STAT5 induced by IL-7 (fig. S4B); signaling by the latter cytokines is dependent on the kinases JAK1 and JAK3 (25). Furthermore, the induction of the *Il5* and *Il13* genes by TSLP was abrogated by the JAK2 inhibitor (Fig. 4B). As expected, the induction of *Gata3* expression by IL-4 signaling was unaffected under these conditions of JAK2 inhibition (Fig. 4B). Surprisingly, the repression of BCL6 by TSLP signaling was not affected by the inhibition of the JAK2-STAT5 pathway (fig. S4C). To validate these results, we used retroviral *Cre*-mediated deletion of the *Stat5a* and *Stat5b* genes in preactivated and rested CD4+ T cells isolated from *Stat5a/5b^fl/fl* mice. In the absence of STAT5 (fig. S4D), TSLP signaling was unable to induce expression of T_H2 cytokine genes (Fig. 4C). Note that TSLP still inhibited BLC6 accumulation in the absence of STAT5A/STAT5B (Fig. 4D). We note

Fig. 3. TSLP induces the expression of T_H2 cytokine genes and represses *Bcl6*. (**A**) Naïve CD4[+] T cells were activated as described in Fig.1A in the presence or absence of IL-4 or TSLP, and transcripts were kinetically profiled by RNA sequencing. The heat map shows genes that were differentially induced by TSLP or IL-4 at the indicated times. Genes shown manifest reads per kilobase of transcript, per million mapped reads (RPKM) of >5 at least one time point and a $\log_2$ fold-change value of >2. Genes that were preferentially induced by TSLP at later times are highlighted in the yellow oval and indicated in the right panel. See table S4 for complete data. (**B**) Real-time quantitative PCR (qPCR) analysis of indicated genes induced in T_H0, T_H2^{IL-4}, and T_H2^{TSLP} cells. Transcript abundance was normalized to that of *Eif3k*, a housekeeping gene. Data are representative of four independent experiments. Data are means ± SD of three technical replicates. (**C**) The kinetics of *Bcl6* expression were analyzed by qPCR. Data are means ± SEM of four experiments. (**D**) Flow cytometry analysis of the percentages of BCL6[+] cells under the indicated conditions. Data are means ± SEM of six experiments. Data in (C) and (D) were analyzed by two-way ANOVA to compare *Bcl6* expression or protein abundance in T_H2^{TSLP} cells to that in T_H0 cells. (**E**) Wild-type (WT) naïve CD4[+] T cells were preactivated with antibodies against CD3, CD28, and IFN-γ for 1 day and then were transduced with retroviruses expressing green fluorescent protein (GFP) or Bcl6-GFP. After an additional 2 days of activation and 1 day of rest in culture medium, the cells were sorted for GFP expression and then reactivated with antibodies against CD3 and CD28 in the presence or absence of TSLP. RNA was isolated after 14 hours and analyzed for *Il4*, *Il5*, and *Il13* transcripts by qPCR. Data are means ± SEM of four experiments. Where statistics are indicated, data were analyzed by two-way ANOVA. *$P \le 0.05$, **$P \le 0.01$, and ***$P \le 0.001$.

Fig. 4. TSLP induction of T_H2 cytokine genes depends on JAK2 and STAT5 activity. (**A**) Naïve *Il4[-/-]* CD4[+] T cells were preincubated for 1 hour with dimethyl sulfoxide (DMSO) or with Janus kinase 2 (JAK2) inhibitor (inh) II (50 μM). Left: The cells were then stimulated with TSLP for 15 min before the phosphorylation of STAT5 was analyzed by flow cytometry, as described in Fig.1C. Right: Data are means ± SEM of five experiments analyzed by ANOVA. (**B**) CD4[+] T cells were activated in the presence of DMSO or JAK2 inhibitor II with or without TSLP or IL-4 for 24 hours, and the abundances of the indicated transcripts were then analyzed. Data are means ± SEM of three experiments analyzed by ANOVA. (**C** and **D**) Naïve *Stat5a/5b[fl/fl]* CD4[+] T cells were preactivated for 1 day and then transduced with retroviruses expressing GFP or Cre-GFP, as described in Fig.3E. The GFP[+] cells were sorted and restimulated with antibodies against CD3 and CD28 with or without TSLP. (C) The abundances of the indicated transcripts were analyzed 14 hours after activation by qPCR. Data are means ± SEM of three experiments and were analyzed by two-way ANOVA. (D) The percentages of BCL6[+] cells were analyzed by flow cytometry 5 hours after reactivation. Data are means ± SEM of three experiments and were analyzed by two-way ANOVA. *$P \le 0.05$, **$P \le 0.01$, ***$P \le 0.001$, and ****$P \le 0.0001$.

periments involving the chemical inhibition of JAK2, when coupled with deletion of the *Stat5a/Stat5b* locus and constitutive expression of *Bcl6*, provide evidence that there are distinct pathways by which TSLP signaling promotes robust T_H2 cell differentiation.

TSLP enhances activating chromatin modifications at T_H2 cytokine loci

We next analyzed the chromatin states of T_H2^{TSLP} versus T_H2^{IL-4} cells by performing chromatin immunoprecipitation sequencing (ChIP-seq) analysis for the activating histone modification, H3K27ac. Consistent

that, in CD4[+] T cells, which were activated and then rested to enable retroviral transduction ("preactivated"), loss of STAT5A/STAT5B resulted in a modest increase in BCL6 abundance. Nevertheless, ex-

with our RNA-seq analysis, most H3K27ac regions that were induced preferentially under T_H2-polarizing conditions (2611 peaks) were shared in T_H2^{IL-4} and T_H2^{TSLP} cells (fig. S5A and table S5). However, there were a small number of H3K27ac regions (90 peaks) that were more highly acetylated in the presence of TSLP. Furthermore, seven of these hyperacetylated chromatin regions occurred within the T_H2 cytokine locus that encodes *Il4*, *Il5*, and *Il13* (Fig. 5A and table S5). Analysis of H3K4me3 by ChIP-seq demonstrated that the hyperacetylated regions around the *Il13* locus were associated with increased H3K4me3 in the presence of TSLP (Fig. 5A). Similar patterns of activating histone modifications, which were dependent on TSLP signaling, were observed near the *Il24* gene (Fig. 5B), which encodes an additional T_H2-type cytokine (26, 27). As anticipated by the analysis of activating histone modifications, the *Il24* gene was more highly expressed in T_H2^{TSLP} cells than in T_H2^{IL-4} cells (fig. S5B). Furthermore, STAT5 activated by TSLP bound to regulatory regions within the T_H2 cytokine and *Faim/Il24* loci, which displayed enhanced H3K27ac and H3K4me3 in T_H2^{TSLP} cells (Fig. 5, A and B).

Given that T_H2^{TSLP} cells depend on an interplay between exogenous TSLP and endogenous IL-4 that is expressed during their differentiation, we examined whether TSLP signaling could induce H3K27ac in the absence of IL-4 at the early time point, when TSLP-mediated expression of T_H2 cytokines was observed (Fig. 2A). ChIP-seq analysis of $Il4^{-/-}$ CD4$^+$ T cells activated in the presence of TSLP for 24 hours revealed that TSLP did not induce H3K27ac at focal regions within the T_H2 cytokine locus in the absence of IL-4 (fig. S5C). Rather, TSLP enhanced IL-4–induced H3K27ac marks. Given that TSLP induced the expression of the *Il5* and *Il13* in the absence of IL-4 signaling within 24 hours of T cell activation (fig. S5D) and that this transcriptional programming was not associated with increased H3K27ac, our results suggest a mechanism for TSLP-activated gene expression that is independent of this histone modification. This mechanism may also function to enhance IL-4–mediated gene activation that is associated with increased H3K27ac.

The TSLP-primed effector state is stably programmed in memory TH2 cells

To determine whether the robust TSLP-primed effector state was stably programmed in memory T_H2 cells, we used an adoptive transfer approach (28, 29). Naïve CD45.1$^+$ CD4$^+$ T cells were differentiated into T_H2^{IL-4} or T_H2^{TSLP} cells (Fig. 1A), and equal numbers were transferred into CD45.2$^+$ recipient mice (Fig. 6A). T_H0 cells were used as controls. The frequency and phenotype of the donor cells (CD45.1$^+$CD4$^+$) were assessed 34 days after transfer. T_H2^{IL-4} or T_H2^{TSLP} cells were recovered in equivalent numbers that were more abundant than their T_H0 counterparts (Fig. 6B). Consistent with their memory phenotype, a large fraction of the T_H2 and T_H2^{TSLP} cells displayed cell surface expression of CD44 and IL-7Rα (CD127) (Fig. 6C). Consistent with their memory T_H2 cell state, the T_H2^{IL-4} and T_H2^{TSLP} cells rapidly increased the abundance of the transcription factors GATA3 and IRF4 after stimulation with antibodies against CD3 and CD28 compared with T_H0 cells and naïve cells (Fig. 6D). Furthermore, they gave rise to an increased frequency of cells producing IL-4, IL-5, or IL-13 (Fig. 6E). Furthermore, memory T_H2^{TSLP} cells manifested a higher frequency of IL-5 and IL-13 producers when compared with conventional

Fig. 6. T_H2^{TSLP} memory cells manifest increased expression of T_H2 cytokines upon reactivation. (**A**) Schematic of the experimental design. Naïve CD45.1$^+$CD4$^+$ T cells activated with antibodies against CD3, CD28, IFN-γ, and IL-4 or TSLP for 3 days and then rested for an additional 3 days in culture medium supplemented with IL-7 (0.5 ng/ml) were transferred into CD45.2$^+$ WT mice. On day 34, total CD4$^+$ T cells were purified from the spleens of the recipient mice and analyzed. (**B**) Numbers of donor cells in the spleens of recipient mice. (**C**) Flow cytometric analysis of the expression of the indicated cell surface markers of memory. (**D**) Analysis of the percentages of cells expressing GATA3 (GATA binding protein 3) or IRF4 after reactivation for 6 hours with antibodies against CD3 and CD28. (**E**) Analysis of the percentages of cells expressing the indicated cytokines after reactivation with antibodies against CD3 and CD28 for 2 days with phorbol 12, 13-dibutyrate (PDBU) and ionomycin added for the last 5 hours. Data were analyzed by one-way ANOVA. Data in (B) to (E) are from donor cells that were gated on CD45.1$^+$CD4$^+$ cells. Data are means ± SEM of four mice for each group and are from one of three representative experiments. For these experiments, naïve CD4 cells were analyzed 12 days after their transfer into WT recipients because these cells have a shorter half-life. (**F**) The indicated CD45.1$^+$ CD4$^+$ T cells were sorted from the spleens of CD45.2$^+$ recipient mice 34 days after transfer. The T cells were then activated for 24 hours with antibodies against CD3 and CD28. H3K27ac was analyzed at the promoter of *Il4* and at downstream regulatory elements of *Il5* and *Il13* by ChIP-PCR. Data are from one of three representative experiments. ****$P \leq 0.0001$.

Fig. 5. TSLP augments activating chromatin modifications in T_H2 cytokine loci. (**A** and **B**) Naïve CD4$^+$ T cells were activated as described in Fig.1A in the presence or absence of IL-4 or TSLP for 3 days and then were analyzed by chromatin immunoprecipitation sequencing (ChIP-seq) for the indicated histone modifications. ChIP-seq tracks for H3K27ac and H3K4me3 are displayed for the T_H2 cytokine locus (A) and the *Faim/Il24/Il20* locus (B) in the indicated effector states. Results are representative of two independent experiments. For the analysis of TSLP-induced STAT5-binding regions in the genome, naïve CD4$^+$ T cells were preactivated for 3 days with antibodies against CD3, CD28, and IFN-γ and then rested for 3 days. On day 7, the cells were left unstimulated or were stimulated with TSLP (40 ng/ml) for 25 min and then analyzed by ChIP-seq for STAT5 binding to chromatin. Histone ChIP-seq data were superimposed with STAT5 ChIP-seq data from TSLP-activated CD4$^+$ T cells.

memory T_H2^{IL-4} cells. This correlated with increased H3K27ac abundance in regulatory regions downstream of the *Il5* and *Il13* genes in memory T_H2^{TSLP} cells after secondary activation (Fig. 6F). These results suggest that TSLP signaling during a primary CD4$^+$ T cell response can stably program a greater effector cytokine output in memory T_H2 cells, which is manifested after secondary activation simply by engagement of the TCR and its co-receptor CD28. Such molecular programming may involve an alteration of chromatin structure that predisposes for increased H3K27 acetylation at the *Il5* and *Il13* genes upon secondary activation.

TSLP signaling in T cells provokes a hyperinflammatory T_H2 response

To test the role of TSLP signaling in CD4$^+$ T cells in enhancing a pathogenic T_H2 cell response, we used the house dust mite (HDM) model of allergic airway inflammation that is widely used for the study of allergic asthma (*30*). *Tcra*$^{-/-}$ mice, which lack endogenous T cells, were reconstituted with WT or TSLPR-deficient (*Crlf2*$^{-/-}$) CD4$^+$ T cells (*31*). One month later, the mice were sensitized with HDM by intratracheal administration (Fig. 7A). This experimental design enabled us to specifically examine the effects of perturbing TSLP signaling in CD4$^+$ T cells while retaining TSLP responsiveness in other immune cells. Analysis of CD4$^+$ T cells in the blood of control and test mice showed comparable numbers of donor cells (Fig. 7B). Upon HDM administration, there was an equivalent increase in the numbers of donor CD4$^+$ T cells in the lungs of both groups of mice. Compared to HDM-exposed mice reconstituted with WT CD4$^+$ T cells, similarly exposed mice reconstituted with *Crlf2*$^{-/-}$ CD4$^+$ T cells manifested a weaker T_H2 inflammatory response, which was characterized by reduced amounts of IL-4, IL-5, and IL-13 (Fig. 7C) and diminished numbers of eosinophils and macrophages in the bronchoalveolar lavage (BAL) fluid (Fig. 7D). Note that the secretion of IFN-γ and IL-17A was not affected (fig. S6A). Consistent with these findings, mice transplanted with *Crlf2*$^{-/-}$ CD4$^+$ T cells manifested reduced bronchial hyper-reactivity to challenge with methacholine (Fig. 7E). Together, these results establish that TSLP signaling in CD4$^+$ T cells is required for a potent T_H2 cell response and exacerbated airway inflammation in the context of HDM sensitization.

To directly compare the T_H2 effector states of WT CD4$^+$ T cells and *Crlf2*$^{-/-}$ CD4$^+$ T cells, we used an OVA model of sensitization with a single antigen challenge. In this model, WT and *Crlf2*$^{-/-}$ CD4$^+$ T cells were transferred into *Tcra*$^{-/-}$ mice, as described previously (Fig. 7A). One month later, the recipient mice were immunized with OVA protein and aluminum hydroxide (ALUM) to induce T_H2 cell differentiation (*15*). Splenic CD4$^+$ T cells were purified on day 7 after immunization and were restimulated in vitro with irradiated splenocytes loaded with OVA protein. *Crlf2*$^{-/-}$ CD4$^+$ T cells produced reduced amounts of T_H2 cytokines compared to WT CD4$^+$ T cells but were not impaired in their ability to secrete IFN-γ (fig. S6B).

To directly assess the percentage of cytokine-producing CD4$^+$ T cells under conditions in which only these cells could respond to TSLP, WT and *Crlf2*$^{-/-}$ naïve CD4$^+$ T cells were transferred into *Crlf2*$^{-/-}$ mice, which were then administered with OVA and ALUM. We found that both donor cell populations proliferated similarly in response to antigen (fig. S6C). Furthermore, WT and *Crlf2*$^{-/-}$ CD4$^+$ T cells gave rise to similar numbers of T_H1 and T_H17 cells. Furthermore, the percentage of IL-13–positive T_H2 cells was substantially reduced by the loss of *Crlf2* in CD4$^+$ T cells (fig. S6D). These results, coupled with our in vitro analyses, suggest that TSLP signaling in CD4$^+$ T

cells specifically enhances their ability to undergo robust differentiation into T_H2 cells, resulting in the increased production of IL-5 and IL-13.

TSLP functions together with IL-4 to induce the expression of T_H2 cytokines by human CD4$^+$ T cells

To assess the effect of TSLP on human CD4$^+$ T cells, such cells were purified from healthy or asthmatic donors and activated in the presence of IL-4, TSLP, or both cytokines (Fig. 8A). Although TSLP and IL-4 alone had modest effects on the expression of T_H2 cytokine genes, in combination, they induced robust increases in the expression of *IL4*, *IL5*, and *IL13* (Fig. 8B), as well as secretion of IL-5 protein (Fig. 8C). Note that, in asthmatic donors, there was more pronounced expression of T_H2 cytokine genes and IL-5 protein. These results suggest that human CD4$^+$ T cells also display a dual requirement for TSLP and IL-4 to enable their robust differentiation into T_H2 cells. Furthermore, such T_H2 cell responses were enhanced in the peripheral T cell compartment of asthmatic children.

Fig. 7. TSLP signaling in CD4$^+$ T cells promotes hyperinflammatory T_H2 response in vivo. (**A** to **D**) WT or *Crlf2*$^{-/-}$ CD4$^+$ T cells were adoptively transferred into *Tcra*$^{-/-}$ mice. Four weeks after T cell reconstitution, the mice were sensitized with 100 μg of house dust mite (HDM) administrated intratracheally (i.t.) on a weekly basis and sacrificed on day 2 after the third HDM injection. (A) Schematic of the experimental design. (B) The percentages of CD4$^+$ T cells in the peripheral blood of indicated mice before HDM injection and in the lung after administration of phosphate-buffered saline (PBS) or HDM were determined by flow cytometry. (C) Analysis of the concentrations of IL-4, IL-5, and IL-13 in the bronchoalveolar lavage (BAL) fluid. (D) Cellular counts in the BAL fluid. Mac, macrophage; Neut, neutrophil; Eos, eosinophil; Lym, lymphocyte; Epi, epithelial cell. Data in (C) and (D) are means ± SEM of eight mice per group and were analyzed by two-tailed, unpaired *t* test. (**E**) Analysis of the airway resistance in the indicated mice in response to increasing concentrations of methacholine. Data are means ± SEM of 10 mice and were analyzed by two-way ANOVA. *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$, and ****$P \leq 0.0001$.

DISCUSSION

To gain insight into the interplay of TSLP and IL-4 in the generation of T_H2 cells, we used an in vitro system in which each signaling pathway could be independently manipulated. Our results suggest that TSLP initiates T_H2 cell programming, involving induction of the expression of the genes encoding IL-4, IL-5, and IL-13, in the absence of IL-4 signaling. However, this transcriptional response was not sustained or amplified in the absence of IL-4 signaling. We note that T cells activated in the presence of TSLP induced the production of IL-4 and increased the abundance of IL-4Rα to establish a feed-forward

Fig. 8. TSLP and IL-4 act in concert to induce the expression of T_H2 cytokines by human CD4+ T cells. (**A** to **C**) Purified human CD4+CD3+ cells isolated from healthy donors (control) or asthmatic donors were activated with anti-CD3 (5 μg/ml), anti-CD28 (2 μg/ml), anti–IFN-γ (5 μg/ml), and IL-4 (40 ng/ml), TSLP (40 ng/ml), or both. (A) Percentage of CD4+CD3+ cells before and after purification. PBMC, peripheral blood mononuclear cell. (B) Analysis of the abundances of RNAs of the indicated genes was measured on day 3 after activation. Data are means ± SEM of six (control) or eight (asthmatic) donors. (C) The amount of IL-5 secreted by the indicated cells was assessed on day 5 after activation. Data are means ± SEM of five (control) or six (asthmatic) donors. The control group contained four children (8 to 9 years of age) and two adults, whereas the asthmatic group contained eight children (5 to 11 years of age). Data were analyzed by one-way ANOVA. *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$, and ****$P \leq 0.0001$.

loop for robust T_H2 cell differentiation that did not require exogenously supplied IL-4. Nonetheless, TSLP signaling promoted T_H2 cell differentiation by pathways that extend beyond the induction of the IL-4 feed-forward loop. This is because, during T_H2 cell differentiation, TSLP specifically increased the frequency of IL-4–, IL-5–. and IL-13–expressing effector cells that had enhanced cytokine production. This was not observed when T cells underwent T_H2 cell differentiation simply in the presence of saturating amounts of exogenous IL-4. A similar effect of TSLP and IL-4 signaling was observed in human CD4+ T cells. In the human context, IL-4 or TSLP signaling induced the production of low amounts of T_H2 cytokines, and the combination of IL-4 and TSLP was necessary for robust T_H2 cell differentiation. Thus, we propose a dual cytokine model for robust T_H2 cell differentiation, involving an interplay of TSLP and IL-4 signaling that is analogous to the interplay among IL-6, IL-21, and IL-23 in the context of T_H17 cell differentiation (*32, 33*) and that of IL-27 and IL-12 in the context of T_H1 cell differentiation (*34*).

IL-2 and STAT5 are essential for T_H2 cell differentiation, both for initiating chromatin accessibility at the *Il4* locus and for increasing expression of the *Il4ra* gene, thereby priming cells for T_H2 cell differentiation (*5, 35–37*). Our current results provide insights into the role of STAT5, suggesting that activation of the STAT5 pathway by TSLP, followed by IL-4 activation of the STAT6-GATA3 pathway, is required for the robust amplification of T_H2 cytokine gene expression and enhanced T_H2 cell differentiation. Surprisingly, IL-7, whose receptor shares the IL-7Rα chain with TSLPR, induced stronger activation of STAT5 than did TSLP but was less effective in promoting T_H2 cell differentiation. A key finding is that TSLP signaling inhibited the induction of *Bcl6* expression during T cell activation in a JAK2- and STAT5-independent manner. BCL6 directly represses *Il4*, *Il9*, and *Il13* expression in CD4+ T cells; thus, its loss leads to increased production of T_H2 cytokines (*23, 38, 39*). Here, we showed that, by antagonizing the induction of BCL6, TSLP promoted the generation of IL-13–expressing cells and magnitude of *Il13* gene expression through a STAT5-independent manner. Hence, we propose that TSLP promotes T_H2 cell differentiation through two distinct molecular pathways: the activation of STAT5 by JAK2 and the repression of *Bcl6* expression, which is not mediated by STAT5. The two pathways appear to function synergistically because STAT5 activation in the presence of sustained *Bcl6* expression did not enable induction of T_H2 cytokine gene expression. Conversely, the TSLP-mediated repression of Bcl6 expression in the absence of STAT5A and STAT5B was not sufficient to activate the expression of *Il5* and *Il13*.

The genomic consequences of TSLP signaling in the first 24 hours of CD4+ T cell activation are highly focused and include the hallmark T_H2 cytokine loci, *Il4*, *Il5*, and *Il13*. Furthermore, this initial transcriptional programming is dependent on the JAK2-STAT5 pathway and can occur in the absence of IL-4 signaling. Note that STAT5 binds to regulatory regions associated with the *Il4*, *Il13*, and *Il9* genes (*39*). Thus, we propose that the initial programming of the T_H2 cell effector state by TSLP signaling involves focal binding and activation by STAT5. This proposal is consistent with the demonstration that expression of a constitutively activated STAT5 protein in naïve CD4+ T cells, primed in the absence of IL-2 signaling, promotes T_H2 cell differentiation even under conditions of IL-4 signaling blockade (*35*). Note that, under conditions of TSLP signaling, the initial activation of expression of the T_H2 cytokine loci by STAT5 was not accompanied by an increase in the activating histone modification H3K27ac at associated regulatory regions. In contrast, the combined

action of TSLP and IL-4 signaling at later stages of T_H2 cell differentiation resulted in an increase in H3K27ac and H3K4me3 at regulatory regions of the T_H2 cytokine loci. These robust histone modifications were not observed with IL-4 alone and were associated with the increased frequency of IL-4–, IL-5–, and IL-13–expressing effector cells with enhanced cytokine production. Thus, underlying our dual cytokine model for robust T_H2 cell differentiation is the sequential and synergistic action of TSLP-activated STAT5 and IL-4–activated STAT6, the latter of which results in the induction of the gene encoding the T_H2 cell transcription factor GATA3. Consistent with this regulatory model, expression of a constitutively activated STAT5 protein, together with GATA3, in activated $CD4^+$ T cells induces more robust T_H2 cell differentiation than does either STAT5 or GATA3 alone (35). The most striking consequence of TSLP signaling in activated $CD4^+$ T cells is that it programs a robust T_H2 effector potential in memory cells. Although this TSLP-primed memory T_H2 state was not associated with increased H3K27 acetylation at regulatory regions of T_H2 cytokine loci, it resulted in enhanced H3K27 acetylation and cytokine gene expression upon secondary activation. The nature of the epigenetic alterations induced by transient TSLP priming that are stably propagated in memory T_H2 cells remains to be explored.

Although it is known that TSLP plays a critical role in allergic disorders and asthma through stimulating DCs (3, 9, 40, 41), its direct action on T cells and T_H2 cell responses in vivo has been underappreciated. A few studies previously investigated a direct effect of TSLP on effector and memory $CD4^+$ T cells in the context of OVA models of allergic diseases (15–17, 42). Here, using the HDM model of airway inflammation, which has pathophysiological features similar to those of human allergic asthma, we demonstrated that $CD4^+$ T cells that responded to TSLP generated more pronounced asthma symptoms. Our in vivo findings highlight the importance of TSLP signaling through its direct actions in promoting robust T_H2 cell differentiation. Our results are consistent with findings that $CD4^+$ T cells that cannot respond to TSLP and IL-33 are impaired in their potential to produce IL-5 and IL-13 in the context of *Nippostrongylus brasiliensis* infection (43).

Distinct T_H2 cell subsets are generated during allergic responses (18, 44–46). Some of these cells produce large amounts of IL-5, IL-9, and IL-13. These cells have been termed pathogenic T_H2 cells. We note that TSLP-primed T_H2 cells (T_H2^{TSLP}) have characteristics of pathogenic T_H2 cells because they produce large amounts of IL-5, IL-9, and IL-13. Furthermore, several genes that are notable in pathogenic T_H17 cells were also strongly expressed in T_H2^{TSLP} cells, such as *Ccl3*, *Ccl4*, *Il3*, and *Csf2*. Consistent with this similarity, TSLP increased activating histone modifications in the *Faim3-Il24* locus; Faim3 is implicated in the pathogenicity of T_H17 cells (33), and IL-24 is suggested to be an additional T_H2-type cytokine (27). These observations suggest that pathogenic T_H2 cells generated by TSLP priming share some features with their T_H17 cell counterparts. We propose that the severity of allergic responses and asthma may be determined by the proportion of conventional T_H2 and pathogenic memory T_H2 cells, the latter generated by TSLP priming. Furthermore, although memory T_H2^{TSLP} cells displayed characteristics shared with IL-4–primed memory T_H2 cells, such as the rapid increased production of GATA3 and IRF4, they manifested an increased capacity to produce IL-5 and IL-13 after restimulation in the absence of TSLP (Fig. 6). Together, our findings suggest that TSLP signaling in naïve $CD4^+$ T cells in conjunction with IL-4 signaling increases the pathogenicity of T_H2 effector and memory cells. Asthmatic children exhibited more pronounced T_H2 cell responses in their peripheral T cell compartment in response to

TSLP and IL-4 signaling. It remains to be determined whether this is due to an increase in the number of pathogenic memory T_H2 cells. Thus, the blockade of TSLP signaling during the priming of allergic T_H2 responses in childhood may prove beneficial in preventing the progression of allergic disorders to severe asthma.

MATERIALS AND METHODS

Study design

The aim of this study was to elucidate the actions and molecular mechanisms by which TSLP induces the differentiation of pathogenic T_H2 cells. The experimental design involved in vitro and in vivo experiments with murine T cells, including flow cytometric, RNA-seq, and ChIP-seq analyses. The animal experiments were not randomized. The investigators were not blinded to the allocation of animals during experiments and analyses. Experimental replication and the numbers of animals used are indicated in the figure legends.

Mice

C57BL/6, *Ptprc^a Pepc^b*/BoyJ (CD45.1), *Tcra^{-/-}*, and *Il4^{-/-}* mice were purchased from The Jackson Laboratory. *Crlf2^{-/-}* mice were described previously (47). These strains were on a C57BL/6 background. *Stat5a/5b^{fl/fl}* mice have been described previously (48) and were back-crossed for multiple generations to BALB/c mice. Both female and male mice (6 to 12 weeks of age) were used for in vivo and in vitro studies. Mice were housed under specific pathogen–free conditions. All experiments complied with protocols approved by the Cincinnati Children's Hospital Medical Center (CCHMC) Animal Use and Care Committee.

T cell isolation and stimulation

Murine lymph node and splenic $CD4^+$ T cells were purified with $CD4^+CD62L^+$ T Cell Isolation kits (Miltenyi Biotec) or sorted as $CD4^+CD62L^{high}CD44^{low}CD25^-$ naïve cells. Purified naïve $CD4^+$ T cells (95 to 98% purity) were activated with plate-bound anti-CD3 (5 μg/ml), soluble anti-CD28 (2 μg/ml), and soluble anti–IFN-γ (10 μg/ml). Each of these antibodies was obtained from BioXCell. T cells were additionally stimulated with TSLP (40 ng/ml; R&D Systems), IL-4 (20 ng/ml; PeproTech), or IL-7 (20 ng/ml; PeproTech). Cells were cultured in RPMI 1640 (Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS), L-glutamine, β-mercapethanol, and antibiotics. To neutralize IL-4, anti–IL-4 (10 μg/ml; 11B11, BioXCell) and anti–IL-4Rα (5 μg/ml; BD Biosciences) were added. The amounts of IL-4, IL-5, and IL-13 secreted by cells into the culture medium were analyzed by enzyme-linked immunosorbent assay (ELISA) with specific kits from R&D Systems. To inhibit JAK2 activation, $CD4^+$ T cells were preincubated for 1 hour with 50 μM JAK2 inhibitor II (CAS 1837-91-8, Calbiochem/Sigma-Aldrich) and then activated for the times indicated in the figure legends in the presence of JAK2 inhibitor II. Dimethyl sulfoxide was used as a control. Human peripheral blood mononuclear cells were isolated by Ficoll gradient centrifugation and then purified with $CD4^+$ T Cell Isolation kits (Miltenyi Biotec) from the whole blood of healthy or asthmatic donors. Purified cells (98% purity) were activated with soluble anti-CD3 (5 μg/ml), anti-CD28 (2 μg/ml; BioXCell), and anti–IFN-γ (5 μg/ml; BioLegend) in the presence or absence of TSLP (40 ng/ml), IL-4 (40 ng/ml), or both.

Retroviral transduction of cells to express *Bcl6* and Cre-mediated deletion of *Stat5a/Stat5b*

Purified $CD4^+$ T cells from WT or *Stat5a/5b^{fl/fl}* mice were preactivated with antibodies against CD3, CD28, and IFN-γ for 1 day. WT

CD4$^+$ T cells were transduced with pMIEG3-BCL6 (a gift from A. Dent; Addgene plasmid 40339), whereas *Stat5a/5b$^{fl/fl}$* cells were transduced with CAG-GFP-IRES-CRE (a gift from F. Gage; Addgene plasmid 48201). MSCV-EcoR1-IRES-GFP (Addgene plasmid 66956) and CAG-GFP (Addgene plasmid 16664) were used as controls for the infections of WT and *Stat5a/5b$^{fl/fl}$* CD4 T cells, respectively. Transduced cells were incubated under activation conditions for an additional 2 days, rested for 24 hours, and then fluorescence-activated cell–sorted on the basis of green fluorescent protein (GFP) expression. GFP$^+$ cells were reactivated with anti-CD3 (2 μg/ml; plate-bound) and anti-CD28 (2 μg/ml; soluble) antibodies with or without TSLP (40 ng/ml). BCL6 protein was detected by intracellular staining 5 hours after activation. RNA was isolated and analyzed 14 hours after activation.

Flow cytometry analysis

For surface marker expression, cells were incubated in staining buffer for 45 min on ice with anti-Fc blocking antibody (2.4G2, BD Biosciences), BV510–anti-CD4, BV711–anti-CD45.1, fluorescein isothiocyanate (FITC)–anti-CD44 (BioLegend), and eFluor 660–anti-CD127 (eBioscience). For intracellular staining of transcription factors, CD4$^+$ T cells were first stained for 20 min with Fixable Viability Dye eFluor 780 to detect dead cells and then fixed and permeabilized with the FoxP3 fixation Kit (eBioscience). Cells were stained with phycoerythrin (PE)–anti-GATA3, and eFluor 660–anti-IRF4 (eBioscience) or allophycocyanin (APC)–anti-BCL6 (BD Biosciences). To detect donor CD45.1 T cells, FITC–anti-CD4 and BV711–anti-CD45.1 monoclonal antibodies (BioLegend) were used. For intracellular staining of cytokines, activated CD4$^+$ T cells were washed and restimulated with phorbol 12, 13-dibutyrate (PDBU) (500 ng/ml; Sigma-Aldrich), 1 μM ionomycin (Sigma-Aldrich), and Brefeldin A (eBioscience) for 5 hours. Harvested cells were fixed and permeabilized with the Cytofix/Cytoperm kit (BD Biosciences) and stained with PE–anti-IL-5, APC–anti–IL-4, eFluor 450–anti-IL-13 (eBioscience), and BV711–anti–IFN-γ (BioLegend). To detect donor CD45.1 T cells, FITC–anti-CD4 and PE–Cy7–anti-CD45.1 (BioLegend) were used. To detect phosphorylated STAT5 (pSTAT5) and pSTAT6, naïve CD4$^+$ T cells were used in the presence of cytokines for 15 min, fixed in Cytofix buffer (BD Biosciences), and permeabilized in 90% methanol on ice. APC anti-pSTAT5 and PE anti-pSTAT6 (BD Biosciences) antibodies were used. Flow cytometry was performed on a Calibur or LSR/Fortessa. To analyze T cell survival, CD4$^+$ T cells were washed in phosphate-buffered saline (PBS), resuspended in 100 μl of annexin V buffer, and stained with FITC–annexin V and 7-amino-actinomycin D (BD Biosciences) for 15 min at room temperature before being analyzed by flow cytometry.

Proliferation assays

Purified naïve CD4$^+$ T cells were labeled for 8 min at room temperature with 2.5 μM carboxyfluorescein diacetate succinimidyl ester (Molecular Probes) and then activated with various concentrations of anti-CD3 antibody in the presence of anti-CD28 and anti–IFN-γ antibodies with or without TSLP for 3 days.

Adoptive transfer and generation of T$_H$2 cells in vivo

Purified naïve polyclonal WT or *Crlf2$^{-/-}$* CD4$^+$ T cells were injected intravenously (2 to 5 × 10^6 cells per mouse) into recipient *Tcra$^{-/-}$* or *Crlf2$^{-/-}$* mice. On day 34 (*Tcra$^{-/-}$*) or on the same day (*Crlf2$^{-/-}$*), mice were immunized intraperitoneally with 100 μg of OVA (Pierce Chemical Co.) in 100 μl of PBS that had been mixed with 4 μg of ALUM (Pierce Chemical Co.). One week later, CD4$^+$ T cells were purified

from the spleens of the immunized mice and cultured with irradiated (3 grays) splenocytes from WT mice in a 1:2 ratio in the presence of 100 μg of OVA protein for 3 days. Cell culture medium was analyzed by ELISA to detect IL-4, IL-5, IL-13, and IFN-γ (R&D Systems) and IL-9 (BioLegend). Cells were stimulated with PDBU (500 ng/ml) and 1 μM ionomycin in the presence of Brefeldin A for 5 hours before intracellular staining of cytokines was performed, as described previously. To generate memory CD4$^+$ T cells, naïve CD45.1$^+$CD4$^+$ T cells was activated with anti-CD3, anti-CD28, anti–IFN-γ antibodies in the presence or absence of TSLP or IL-4 for 3 days, rested in medium containing IL-7 (0.5 ng/ml) for 3 days, and injected intravenously (10^7 cells per mouse) into recipient CD45.2$^+$ WT mice. Five weeks later, total CD4$^+$ T cells were isolated from the spleens of recipient mice and stained or activated as indicated in the figure legends. Donor cells were gated on the basis of CD45.1 expression. For ChIP experiments, donor CD45.1$^+$CD4$^+$ T cells were sorted.

Murine HDM asthma model

Tcra$^{-/-}$ mice were injected with 5 × 10^6 to 6 × 10^6 WT or *Crlf2$^{-/-}$* purified naïve CD4$^+$ T cells. One month later, the mice were anesthetized with ketamine/xylazine, which was followed by intratracheal administration of either 40 μl of PBS or 100 μg of HDM in 40 μl of PBS (Greer Laboratories). HDM was administered two additional times at 1-week intervals. Two days after the last challenge, the mice were sacrificed by pentobarbital injection, and the organs were dissected for analysis. BAL fluid was collected with 1 ml of PBS by cannulation of the trachea and centrifuged at 500g for 5 min. The supernatant was used for the measurement of cytokines by ELISA. The cell pellet was resuspended in PBS containing 2% FBS and centrifuged in a Cytospin at 500g for 5 min. Slides were stained with KWIK-DIFF Stain kit (Thermo Fisher Scientific) to enable morphology-based cell counts. At least 200 cells in random fields were counted for each sample. Lung function analysis was performed using a flexiVent invasive measurement of dynamic resistance, as described previously (*49*).

RNA isolation and analyses

Naïve CD4$^+$ T cells were activated with antibodies against CD3, CD28, and IFN-γ in the presence or absence of TSLP or IL-4 for 0, 2, 6, 24, 48, and 72 hours. RNA was isolated using the Aurum Total RNA kit (Bio-Rad). For real-time PCR analysis, RNA was reverse-transcribed with the iScript cDNA Synthesis kit (Bio-Rad). All primers and probes were purchased from Integrated DNA Technologies (IDT) (table S6). The ABI 7900HT Fast Sequence Detection System was used to quantitate PCR products. The abundances of the transcripts of interest were determined relative to that of *Eif3k* complementary DNA (cDNA). For RNA-seq analysis, mRNA was purified from total RNA with the Dynabeads mRNA Purification kit (Invitrogen) and reverse-transcribed with the SuperScript Double-Stranded cDNA Synthesis kit (Invitrogen). The deoxyuridine triphosphate (dUTP) method was used for the preparation of RNA-seq libraries. Next-generation RNA-seq was performed by the CCHMC DNA Sequencing and Genotyping Core with Illumina TruSeq kits and an Illumina HiSeq 2000 sequencing system, which resulted in ~20 million paired-end reads per sample. RNA-seq data are available from the Gene Expression Omnibus (GEO) database (accession number: GSE81384). RNA-seq data analysis was performed with BioWardrobe (*50*). Briefly, reads were mapped with RNA-STAR 23104886, and reads per kilobase of transcript, per million mapped reads (RPKM) calculations were performed with the BioWardrobe algorithm. Differential gene expression analysis was performed with

DESeq2 (51). Genes were considered to be differentially expressed if $P_{adj} \leq 0.05$ for at least one time point. Two additional cutoffs were used: a change in expression of more than twofold (higher or lower) and an RPKM value of ≥ 5 in at least one sample. Biological processes and pathway analyses for gene clusters were assigned with ToppGene software (52).

Chromatin immunoprecipitation sequencing

Cells were cross-linked with 1% formaldehyde for 8 min, and chromatin was prepared as previously described (53). Sonication was performed with a Covaris S220 focused ultrasonicator (Covaris Inc.) at 175-W peak incident power, 10% output, and 200 bursts for 5 min. DNA fragmentation was verified by agarose gel electrophoresis. ChIP was performed with a rabbit polyclonal anti-H3K27ac antibody (Diagenode Inc.), a rabbit monoclonal anti-H3K4me3 antibody (17-614, Millipore), or a rabbit polyclonal anti-STAT5A/5B antibody (AF1584, R&D Systems) and Dynabeads Protein G (Invitrogen) in radioimmunoprecipitation assay buffer (10 mM tris-EDTA, 0.1% SDS, 1% Triton X-100, 150 mM NaCl, and 0.1% sodium deoxycholate). ChIP DNA was converted into indexed libraries with the ThruPLEX DNA-seq kit (Rubicon) and was sequenced on an Illumina HiSeq 2000 sequencing system, which resulted in ~20 to 40 million single-end reads per sample. Data analysis was performed in BioWardrobe (50). Briefly, reads were mapped with BowTie and displayed on a local mirror of the UCSC genome browser as coverage by estimated fragments. Peaks were identified by MACS2, and differential enrichment was analyzed with MAnorm. ChIP-seq data are available from the GEO database (accession number: GSE81384). For ChIP-PCR, IDT primers and probes labeled with fluorescein amidite were used (table S7).

Statistical analyses

All statistical analyses were performed with Prism 6 software (GraphPad Software Inc.), as described in the figure legends: $*P \leq 0.05$, $**P \leq 0.01$, $***P \leq 0.001$, and $****P \leq 0.0001$.

SUPPLEMENTARY MATERIALS

www.sciencesignaling.org/cgi/content/full/11/521/eaam8858/DC1

Fig. S1. TSLP promotes T_H2 cell differentiation without affecting the survival or proliferation of activated $CD4^+$ T cells.

Fig. S2. TSLP enhances IL-4Rα abundance and promotes T_H2 cell differentiation in synergy with IL-4.

Fig. S3. Comparative transcriptional analysis of T_H2^{IL-4} and T_H2^{TSLP} cells.

Fig. S4. JAK2 inhibitor II selectively blocks the TSLP-mediated activation of STAT5.

Fig. S5. Comparative chromatin analysis of T_H2^{IL-4} and T_H2^{TSLP} cells.

Fig. S6. TSLP-responsive $CD4^+$ T cells, sensitized in vivo, manifest enhanced production of T_H2 cytokines.

Table S1. Quantitative analysis of IL-13–positive $CD4^+$ T cells and the amounts of secreted IL-5 and IL-13.

Table S2. RNA-seq analysis of the gene expression profiles of T_H2^{IL-4} and T_H2^{TSLP} cells compared to that of T_H0 cells.

Table S3. RNA-seq analysis of gene expression clusters and pathways in T_H0, T_H2, and T_H2^{TSLP} cells.

Table S4. RNA-seq analysis of the gene expression profile of T_H2^{TSLP} cells compared to that of T_H2^{IL-4} cells.

Table S5. H3K27ac ChIP-seq tag density coordinates, 2.5-kb intervals around peak centers for shared peaks or peaks specific for T_H2 and T_H2^{TSLP} cells.

Table S6. Primers for PCR.

Table S7. Primers and probes for ChIP-DNA H3K27ac.

REFERENCES AND NOTES

1. W. E. Paul, J. Zhu, How are T_H2-type immune responses initiated and amplified? *Nat. Rev. Immunol.* **10**, 225–235 (2010).
2. W. E. Paul, History of interleukin-4. *Cytokine* **75**, 3–7 (2015).
3. S. F. Ziegler, D. Artis, Sensing the outside world: TSLP regulates barrier immunity. *Nat. Immunol.* **11**, 289–293 (2010).
4. P. Licona-Limón, L. K. Kim, N. W. Palm, R. A. Flavell, T_H2, allergy and group 2 innate lymphoid cells. *Nat. Immunol.* **14**, 536–542 (2013).
5. W. Liao, J.-X. Lin, W. J. Leonard, Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. *Immunity* **38**, 13–25 (2013).
6. M. Kashyap, Y. Rochman, R. Spolski, L. Samsel, W. J. Leonard, Thymic stromal lymphopoietin is produced by dendritic cells. *J. Immunol.* **187**, 1207–1211 (2011).
7. M. J. Elder, S. J. Webster, D. L. Williams, J. S. H. Gaston, J. C. Goodall, TSLP production by dendritic cells is modulated by IL-1β and components of the endoplasmic reticulum stress response. *Eur. J. Immunol.* **46**, 455–463 (2016).
8. F. Roan, B. D. Bell, T. A. Stoklasek, M. Kitajima, H. Han, S. F. Ziegler, The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond. *J. Leukoc. Biol.* **91**, 877–886 (2012).
9. V. Soumelis, P. A. Reche, H. Kanzler, W. Yuan, G. Edward, B. Homey, M. Gilliet, S. Ho, S. Antonenko, A. Lauerma, K. Smith, D. Gorman, S. Zurawski, J. Abrams, S. Menon, T. McClanahan, R. de Waal-Malefyt, F. Bazan, R. A. Kastelein, Y.-J. Liu, Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat. Immunol.* **3**, 673–680 (2002).
10. T. Ito, Y.-H. Wang, O. Duramad, T. Hori, G. J. Delespesse, N. Watanabe, F. X.-F. Qin, Z. Yao, W. Cao, Y.-J. Liu, TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. *J. Exp. Med.* **202**, 1213–1223 (2005).
11. I. Rochman, N. Watanabe, K. Arima, Y.-J. Liu, W. J. Leonard, Cutting edge: Direct action of thymic stromal lymphopoietin on activated human $CD4^+$ T cells. *J. Immunol.* **178**, 6720–6724 (2007).
12. M. Omori, S. Ziegler, Induction of IL-4 expression in $CD4^+$ T cells by thymic stromal lymphopoietin. *J. Immunol.* **178**, 1396–1404 (2007).
13. R. He, M. K. Oyoshi, L. Garibyan, L. Kumar, S. F. Ziegler, R. S. Geha, TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 11875–11880 (2008).
14. Y. Rochman, M. Kashyap, G. W. Robinson, K. Sakamoto, J. Gomez-Rodriguez, K.-U. Wagner, W. J. Leonard, Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 19455–19460 (2010).
15. A. Al-Shami, R. Spolski, J. Kelly, A. Keane-Myers, W. J. Leonard, A role for TSLP in the development of inflammation in an asthma model. *J. Exp. Med.* **202**, 829–839 (2005).
16. A. B. Blazquez, L. Mayer, M. C. Berin, Thymic stromal lymphopoietin is required for gastrointestinal allergy but not oral tolerance. *Gastroenterology* **139**, 1301–1309.e4 (2010).
17. Q. Wang, J. Du, J. Zhu, X. Yang, B. Zhou, Thymic stromal lymphopoietin signaling in $CD4^+$ T cells is required for T_H2 memory. *J. Allergy Clin. Immunol.* **135**, 781–791.e3 (2015).
18. W. Yao, Y. Zhang, R. Jabeen, E. T. Nguyen, D. S. Wilkes, R. S. Tepper, M. H. Kaplan, B. Zhou, Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. *Immunity* **38**, 360–372 (2013).
19. M. Kitajima, H.-C. Lee, T. Nakayama, S. F. Ziegler, TSLP enhances the function of helper type 2 cells. *Eur. J. Immunol.* **41**, 1862–1871 (2011).
20. J. Rengarajan, K. A. Mowen, K. D. McBride, E. D. Smith, H. Singh, L. H. Glimcher, Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. *J. Exp. Med.* **195**, 1003–1012 (2002).
21. K. Man, M. Miasari, W. Shi, A. Xin, D. C. Henstridge, S. Preston, M. Pellegrini, G. T. Belz, G. K. Smyth, M. A. Febbraio, S. L. Nutt, A. Kallies, The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. *Nat. Immunol.* **14**, 1155–1165 (2013).
22. A. Pandey, K. Ozaki, H. Baumann, S. D. Levin, A. Puel, A. G. Farr, S. F. Ziegler, W. J. Leonard, H. F. Lodish, Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. *Nat. Immunol.* **1**, 59–64 (2000).
23. X. Liu, H. Lu, T. Chen, K. C. Nallaparaju, X. Yan, S. Tanaka, K. Ichiyama, X. Zhang, L. Zhang, X. Wen, Q. Tian, X.-w. Bian, W. Jin, L. Wei, C. Dong, Genome-wide analysis identifies Bcl6-controlled regulatory networks during T follicular helper cell differentiation. *Cell Rep.* **14**, 1735–1747 (2016).
24. E. M. Sandberg, X. Ma, K. He, S. J. Frank, D. A. Ostrov, P. P. Sayeski, Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation. *J. Med. Chem.* **48**, 2526–2533 (2005).
25. Y. Rochman, R. Spolski, W. J. Leonard, New insights into the regulation of T cells by γc family cytokines. *Nat. Rev. Immunol.* **9**, 480–490 (2009).
26. M. Wang, P. Liang, Interleukin-24 and its receptors. *Immunology* **114**, 166–170 (2005).
27. S. Commins, J. W. Steinke, L. Borish, The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. *J. Allergy Clin. Immunol.* **121**, 1108–1111 (2008).
28. C. A. London, V. L. Perez, A. K. Abbas, Functional characteristics and survival requirements of memory $CD4^+$ T lymphocytes in vivo. *J. Immunol.* **162**, 766–773 (1999).
29. M. Yamashita, R. Shinnakasu, Y. Nigo, M. Kimura, A. Hasegawa, M. Taniguchi, T. Nakayama, Interleukin (IL)-4-independent maintenance of histone modification of the IL-4 gene loci in memory Th2 cells. *J. Biol. Chem.* **279**, 39454–39464 (2004).

30. L. G. Gregory, C. M. Lloyd, Orchestrating house dust mite-associated allergy in the lung. *Trends Immunol.* **32**, 402–411 (2011).

31. M. Mohrs, K. Shinkai, K. Mohrs, R. M. Locksley, Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter. *Immunity* **15**, 303–311 (2001).

32. L. Zhou, I. I. Ivanov, R. Spolski, R. Min, K. Shenderov, T. Egawa, D. E. Levy, W. J. Leonard, D. R. Littman, IL-6 programs T_H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. *Nat. Immunol.* **8**, 967–974 (2007).

33. J. T. Gaublomme, N. Yosef, Y. Lee, R. S. Gertner, L. V. Yang, C. Wu, P. P. Pandolfi, T. Mak, R. Satija, A. K. Shalek, V. K. Kuchroo, H. Park, A. Regev, Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. *Cell* **163**, 1400–1412 (2015).

34. S. Pflanz, J. C. Timans, J. Cheung, R. Rosales, H. Kanzler, J. Gilbert, L. Hibbert, T. Churakova, M. Travis, E. Vaisberg, W. M. Blumenschein, J. D. Mattson, J. L. Wagner, S. To, S. Zurawski, T. K. McClanahan, D. M. Gorman, J. F. Bazan, R. de Waal Malefyt, D. Rennick, R. A. Kastelein, IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. *Immunity* **16**, 779–790 (2002).

35. J. Zhu, J. Cote-Sierra, L. Guo, W. E. Paul, Stat5 activation plays a critical role in Th2 differentiation. *Immunity* **19**, 739–748 (2003).

36. J. Cote-Sierra, G. Foucras, L. Guo, L. Chiodetti, H. A. Young, J. Hu-Li, J. Zhu, W. E. Paul, Interleukin 2 plays a central role in Th2 differentiation. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 3880–3885 (2004).

37. W. Liao, D. E. Schones, J. Oh, Y. Cui, K. Cui, T.-Y. Roh, K. Zhao, W. J. Leonard, Priming for T helper type 2 differentiation by interleukin 2–mediated induction of interleukin 4 receptor α-chain expression. *Nat. Immunol.* **9**, 1288–1296 (2008).

38. A. L. Dent, A. L. Shaffer, X. Yu, D. Allman, L. M. Staudt, Control of inflammation, cytokine expression, and germinal center formation by BCL-6. *Science* **276**, 589–592 (1997).

39. W. Liao, R. Spolski, P. Li, N. Du, E. E. West, M. Ren, S. Mitra, W. J. Leonard, Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 3508–3513 (2014).

40. Y.-J. Liu, V. Soumelis, N. Watanabe, T. Ito, Y.-H. Wang, R. de Waal Malefyt, M. Omori, B. Zhou, S. F. Ziegler, TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. *Annu. Rev. Immunol.* **25**, 193–219 (2007).

41. H. Han, T. D. Thelen, M. R. Comeau, S. F. Ziegler, Thymic stromal lymphopoietin-mediated epicutaneous inflammation promotes acute diarrhea and anaphylaxis. *J. Clin. Invest.* **124**, 5442–5452 (2014).

42. S. Jang, S. Morris, N. W. Lukacs, TSLP promotes induction of Th2 differentiation but is not necessary during established allergen-induced pulmonary disease. *PLOS ONE* **8**, e56433 (2013).

43. S. J. Van Dyken, J. C. Nussbaum, J. Lee, A. B. Molofsky, H.-E. Liang, J. L. Pollack, R. E. Gate, G. E. Haliburton, C. J. Ye, A. Marson, D. J. Erle, R. M. Locksley, A tissue checkpoint regulates type 2 immunity. *Nat. Immunol.* **17**, 1381–1387 (2016).

44. C. Prussin, Y. Yin, B. Upadhyaya, T_H2 heterogeneity: Does function follow form? *J. Allergy Clin. Immunol.* **126**, 1094–1098 (2010).

45. B. Upadhyaya, Y. Yin, B. J. Hill, D. C. Douek, C. Prussin, Hierarchical IL-5 expression defines a subpopulation of highly differentiated human Th2 cells. *J. Immunol.* **187**, 3111–3120 (2011).

46. Y. Endo, K. Hirahara, R. Yagi, D. J. Tumes, T. Nakayama, Pathogenic memory type Th2 cells in allergic inflammation. *Trends Immunol.* **35**, 69–78 (2014).

47. A. Al-Shami, R. Spolski, J. Kelly, T. Fry, P. L. Schwartzberg, A. Pandey, C. L. Mackall, W. J. Leonard, A role for thymic stromal lymphopoietin in CD4+ T cell development. *J. Exp. Med.* **200**, 159–168 (2004).

48. Y. Cui, G. Riedlinger, K. Miyoshi, W. Tang, C. Li, C.-X. Deng, G. W. Robinson, L. Hennighausen, Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. *Mol. Cell. Biol.* **24**, 8037–8047 (2004).

49. I. P. Lewkowich, S. Lajoie, S. L. Stoffers, Y. Suzuki, P. K. Richgels, K. Dienger, A. A. Sproles, H. Yagita, Q. Hamid, M. Wills-Karp, PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production. *Mucosal Immunol.* **6**, 728–739 (2013).

50. A. V. Kartashov, A. Barski, BioWardrobe: An integrated platform for analysis of epigenomics and transcriptomics data. *Genome Biol.* **16**, 158 (2015).

51. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

52. J. Chen, E. E. Bardes, B. J. Aronow, A. G. Jegga, ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* **37**, W305–W311 (2009).

53. M. Rochman, A. V. Kartashov, J. M. Caldwell, M. H. Collins, E. M. Stucke, K. Kc, J. D. Sherrill, J. Herren, A. Barski, M. E. Rothenberg, Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation. *Mucosal Immunol.* **8**, 785–798 (2015).

Citation: Y. Rochman, K. Dienger-Stambaugh, P. K. Richgels, I. P. Lewkowich, A. V. Kartashov, A. Barski, G. K. Khurana Hershey, W. J. Leonard, H. Singh, TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state. *Sci. Signal.* **11**, eaam8858 (2018).

Science Signaling

TSLP signaling in CD4[+] T cells programs a pathogenic T helper 2 cell state

Yrina Rochman, Krista Dienger-Stambaugh, Phoebe K. Richgels, Ian P. Lewkowich, Andrey V. Kartashov, Artem Barski, Gurjit K. Khurana Hershey, Warren J. Leonard and Harinder Singh

TSLP as a therapeutic target

Although T helper 2 (T$_H$2) cells mediate immunity against extracellular parasites, they also promote allergic inflammation. The cytokine interleukin-4 (IL-4), which is produced by T$_H$2 cells, is also required for their differentiation. Noting that the cytokine TSLP is implicated in the pathogenesis of T$_H$2 cell–associated allergic disorders, Rochman *et al.* investigated its role in T$_H$2 cell differentiation. They found that T$_H$2 cells that differentiated in the presence of TSLP and IL-4 produced increased amounts of cytokines and were more pathogenic compared to T$_H$2 cells differentiated in the presence of IL-4 alone. Mice that received CD4[+] T cells deficient in the TSLP receptor had reduced allergic responses compared to those that received wild-type cells. Given that pediatric asthma patients had enhanced T$_H$2 cytokine production compared to that of healthy controls, these data suggest that TSLP may be a therapeutic target in allergic diseases.

ARTICLE TOOLS	http://stke.sciencemag.org/content/11/521/eaam8858
SUPPLEMENTARY MATERIALS	http://stke.sciencemag.org/content/suppl/2018/03/09/11.521.eaam8858.DC1
RELATED CONTENT	http://stke.sciencemag.org/content/sigtrans/10/475/eaan3693.full http://science.sciencemag.org/content/sci/351/6279/1329.full http://science.sciencemag.org/content/sci/356/6342/1026.full http://stm.sciencemag.org/content/scitransmed/8/337/337ra65.full http://stm.sciencemag.org/content/scitransmed/9/401/eaam9171.full http://immunology.sciencemag.org/content/immunology/1/5/eaaf8471.full
REFERENCES	This article cites 53 articles, 16 of which you can access for free http://stke.sciencemag.org/content/11/521/eaam8858#BIBL
PERMISSIONS	http://www.sciencemag.org/help/reprints-and-permissions